2019-LB: Improvement in Glycemic Control with Dexcom CGM Use in Adults in Germany with Type 2 Diabetes on Basal Insulin

Résumé fourni par la source

Introduction and Objective: The aim of this real-world, retrospective study was to evaluate CGM-measured glycemic control over 3 months of use in adults in Germany with type 2 diabetes (T2D) on basal insulin, who have limited insurance reimbursement for CGM. Methods: Preliminary data were analyzed from Dexcom G7 users in Germany who self-reported: T2D, ≥18 years of age, gender, only basal insulin use, met CGM data sufficiency criteria at baseline and 3 months, and had baseline time in range 70-180 mg/dL (TIR) ≤70%. Outcomes were change in CGM metrics from baseline to 3 months and the proportion with TIR >70% at 3 months. Results: Overall, CGM users (n=69) were mean (SD) 60.4 (9.8) years, 23% female, diabetes duration 12.8 (8.7) years and baseline TIR 46.7% (20.3%). Significant improvements were observed at 3 months (Table) for CGM metrics not meeting target values at baseline. Time in range increased by 11.0% (24.7%) and time in tight range (TITR) 70-140 mg/dL increased by 9.1% (19.0%) which was attributed to decreased time in hyperglycemia (both p<0.001). The proportion of CGM users meeting the target of TIR >70% increased from 0% to 33.3%. Conclusion: In this real-world study of adults in Germany with T2D on basal insulin only, Dexcom CGM use was associated with clinically meaningful improvements in glycemic control at 3 months supporting the potential benefits of expanded access. Disclosure Y. Haufe: Employee; Dexcom, Inc. Consultant; WH Pharmawerk Weinböhla. J. Tomlin: None. C. Griffen: Employee; Dexcom, Inc. J.E. Layne: Employee; Dexcom, Inc.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.